Our top pick for
Building a portfolio
Adverum Biotechnologies, Inc is a biotechnology business based in the US. Adverum Biotechnologies shares (ADVM) are listed on the NASDAQ and all prices are listed in US Dollars. Adverum Biotechnologies employs 167 staff and has a market cap (total outstanding shares value) of USD0.00.
|52-week range||USD$8.75 - USD$26.98|
|50-day moving average||USD$10.625|
|200-day moving average||USD$12.0025|
|Wall St. target price||USD$24.89|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.046|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Gross profit TTM||USD$-73,309,000|
|Return on assets TTM||-20.9%|
|Return on equity TTM||-38.57%|
|Market capitalisation||USD$896.8 million|
TTM: trailing 12 months
There are currently 11.4 million Adverum Biotechnologies shares held short by investors – that's known as Adverum Biotechnologies's "short interest". This figure is 11.2% up from 10.2 million last month.
There are a few different ways that this level of interest in shorting Adverum Biotechnologies shares can be evaluated.
Adverum Biotechnologies's "short interest ratio" (SIR) is the quantity of Adverum Biotechnologies shares currently shorted divided by the average quantity of Adverum Biotechnologies shares traded daily (recently around 848072.1641791). Adverum Biotechnologies's SIR currently stands at 13.4. In other words for every 100,000 Adverum Biotechnologies shares traded daily on the market, roughly 13400 shares are currently held short.
However Adverum Biotechnologies's short interest can also be evaluated against the total number of Adverum Biotechnologies shares, or, against the total number of tradable Adverum Biotechnologies shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Adverum Biotechnologies's short interest could be expressed as 0.12% of the outstanding shares (for every 100,000 Adverum Biotechnologies shares in existence, roughly 120 shares are currently held short) or 0.126% of the tradable shares (for every 100,000 tradable Adverum Biotechnologies shares, roughly 126 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Adverum Biotechnologies.
Find out more about how you can short Adverum Biotechnologies stock.
We're not expecting Adverum Biotechnologies to pay a dividend over the next 12 months.
Over the last 12 months, Adverum Biotechnologies's shares have ranged in value from as little as $8.75 up to $26.98. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Adverum Biotechnologies's is 1.4573. This would suggest that Adverum Biotechnologies's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Adverum Biotechnologies, Inc. , a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal diseases, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc.
Features, fees and complaints to consider before you apply for a T. Rowe Price account.
Steps to owning and managing ZTO, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZOM, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZKIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZION, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZNTL, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZGYH, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZEAL, with 24-hour and historical pricing before you buy.
Steps to owning and managing CTIB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.